RXSIGHT INC. DL -,001

RxSight appointed Aziz Mottiwala, effective July 20, as president and chief executive officer; he replaces Dr. Ron Kurtz, who will move to chief medical officer and leave the board of directors, while Mottiwala will be named to the board. Mottiwala joins from Tarsus Pharmaceuticals and brings experience in senior sales and commercial roles in ophthalmology. The stock is under pressure (about −8% last week, −50% over six months) and is trading at $5.25 (market capitalization $216.92 million). The company manufactures the Light Adjustable Lens System and said it would not change its prior financial guidance. » More on de.investing.com

RxSight lowered its 2026 revenue forecast to $110–120 million (previously $120–135 million), triggering a roughly 12.9% share price decline. The total revenue outlook of $140–160 million includes $30–40 million from the Alcon collaboration; preliminary Q2 revenues are expected at $32–34 million ( $5–7 million from the Alcon partnership, about $27 million from product sales). The company cited "significant commercial headwinds" and plans to accelerate sales investments while maintaining spending discipline; gross margin guidance was raised to 73–75%, and operating expenses remain at the high end of the $150–160 million range. Cash and equivalents totaled about $209 million as of June 30; RxSight is working on a next generation of Light Adjustable Lens products. » More on de.investing.com

RxSight expects Q2 revenue of about $32–34 million, including $5–7 million from a collaboration with Alcon; product revenue was roughly $27 million from 24,917 Light Adjustable Lens units sold. The company lowers its 2026 revenue outlook to $140–160 million (product revenue $110–120 million) and still anticipates $30–40 million from the Alcon agreement. RxSight raises its gross margin to 73–75% but expects operating expenses at the high end of the $150–160 million range and cites increased competitive testing as commercial headwind. The company plans to accelerate sales investments, develop new generations of LAL, and will release full Q2 figures on August 5. » More on de.investing.com